Search

Ivabradine

Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. … Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate

Quinine

Quinine (GLS-1200) was also investigated in clinical trials for its efficacy in preventing SARS-CoV-2 infection (NCT04408183, terminated) and is planned to be evaluated for preventing sinusitis after endoscopic … Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose.

AV608

AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).

Vanglusagene ensiparvovec

Repaglinide

Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight.

Revefenacin

The LAMA group falls into a parent category known as long-acting inhaled bronchodilators and this type of agents are recommended as a maintenance therapy for chronic obstructive pulmonary disease (COPD … [A40025] From the LAMA group, revefenacin is the first once-daily nebulized LAMA treatment.[A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]

Pergolide

Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. … While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes.

Patisiran

It is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. … The approval for Onpattro was granted to Alnylam Pharmaceuticals, Inc. in August of 2018. Onpattro has been granted Fast Track, Priority Review and Breakthrough Therapy, and Orphan Drug designations.

Bamlanivimab

for progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns. … [L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children.[L40179]